Rege Nephro
Develops regenerative kidney disease therapies, including RN-014, with recent funding to advance the program toward commercialization.
Overview
Rege Nephro is a regenerative medicine company focused on kidney disease, with RN-014 identified as its lead program moving toward commercialization. Its work targets patients and healthcare providers in nephrology, a market with significant unmet need for disease-modifying therapies. The company raised about $11 million in an undisclosed round announced in July 2026, described as approximately $10.6 million to advance RN-014. Although listed under AI, the available context points to a biotechnology and regenerative therapy business rather than an AI company.
Funding History
Rege Nephro Secures approximately US$10.6 Million to Advance RN-014 Toward Commercialization
Frequently Asked Questions
- How much has Rege Nephro raised in total?
- Rege Nephro has raised a total of $11M across 1 funding round.
- What does Rege Nephro do?
- Rege Nephro is a regenerative medicine company focused on kidney disease, with RN-014 identified as its lead program moving toward commercialization. Its work targets patients and healthcare providers in nephrology, a market with significant unmet need for disease-modifying therapies. The company raised about $11 million in an undisclosed round announced in July 2026, described as approximately $10.6 million to advance RN-014. Although listed under AI, the available context points to a biotechnology and regenerative therapy business rather than an AI company.
- Where is Rege Nephro headquartered?
- Rege Nephro is headquartered in Kyoto, Japan.
Related Insights
A comprehensive analysis of Isembard's funding history, investors, competitive position, and growth trajectory in the Deep Tech space.
Compare the leading AI-focused VC firms: Andreessen Horowitz, Sequoia Capital, Thrive Capital, and 7 more. Analysis of 150+ AI deals, investment strategies, sector focus, and portfolio performance.
395 AI funding deals worth $337B tracked in 2026. Complete guide to raising pre-seed, seed, Series A/B/C+ for AI startups. Valuations, metrics VCs demand, top investors (Sequoia, a16z, Lightspeed), and how AI funding differs from traditional tech. Includes real deal sizes, timelines, and founder strategies.